"Or an IA was done and is showing PFS isn't great, yet OS is good, and the company is trying to use iRANO to support why PFS is not good and amend for a co-endpoint to continue the trial. Perhaps the regulators wanted evidence of all imaging and upon review regulators will agree."
Yes, and this fits with both Bosch's pseduo progressives wreck havoc, and LL's everyone is living longer and comparing early DCVAX vs later DCVAX (OS analysis) comments. Again, if the PFS data were a grand slam, why would they need to do all of this?
News 
Market Data 
Discover 
AI
